Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.7% – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price traded down 5.7% during mid-day trading on Monday . The stock traded as low as $26.41 and last traded at $26.41. 52,164 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 192,814 shares. The stock had previously closed at $28.00.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Oppenheimer assumed coverage on Dianthus Therapeutics in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $48.00 price objective for the company. Lifesci Capital raised Dianthus Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Cantor Fitzgerald began coverage on Dianthus Therapeutics in a research note on Thursday, June 27th. They set an “overweight” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Thursday, September 26th. Nine investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Buy” and a consensus price target of $45.13.

Dianthus Therapeutics Stock Performance

The stock has a 50 day moving average of $27.80 and a two-hundred day moving average of $26.19. The firm has a market capitalization of $824.71 million, a P/E ratio of -4.78 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The company had revenue of $1.86 million during the quarter, compared to the consensus estimate of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. Sell-side analysts predict that Dianthus Therapeutics, Inc. will post -2.32 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at approximately $112,000. The Manufacturers Life Insurance Company acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at approximately $236,000. WINTON GROUP Ltd acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at approximately $265,000. Point72 DIFC Ltd acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at approximately $334,000. Finally, Virtu Financial LLC acquired a new stake in Dianthus Therapeutics in the 1st quarter valued at approximately $390,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.